LGALS3 and type 1 diabetes mellitus: To address the role of Galectin-3 in T1D pathogenesis, we first used the CRISPR-Cas9 approach for gene editing of the Lgals3 locus, thereby generating Galectin-3−/− NOD mice (fig.